Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:54:06 ON 20 APR 2009

=> file medline, uspatful, dgene, embase, wpids, hcaplus, biotechds,
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.44       0.44

FILE 'MEDLINE' ENTERED AT 12:55:08 ON 20 APR 2009

FILE 'USPATFULL' ENTERED AT 12:55:08 ON 20 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:55:08 ON 20 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 12:55:08 ON 20 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:55:08 ON 20 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'HCAPLUS' ENTERED AT 12:55:08 ON 20 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHDS' ENTERED AT 12:55:08 ON 20 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> s (PAI-1 and disulfide bond)
L1          406 (PAI-1 AND DISULFIDE BOND)

=> s l1 and (sulfhydryl group)
L2           69 L1 AND (SULFHYDRYL GROUP)

=> s l2 and (cysteine)
L3           66 L2 AND (CYSTEINE)

=> s l2 and (position 31 or 97)
L4           61 L2 AND (POSITION 31 OR 97)

=> s l4 and (position 192 or 197)
L5           42 L4 AND (POSITION 192 OR 197)

=> d l5 ti abs ibib 1-14
```

L5 ANSWER 1 OF 42 USPATFULL on STN
TI METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
AB The present invention relates to chemically modified, linked double-stranded (ds)RNA compositions comprising two or more double-stranded (ds) oligoribonucleotides linked by at least one linking moiety and methods of formulating and delivering such compositions to modulate gene expression through target-specific RNA co-interference (RNAco-i). The compositions of the invention may optionally comprise a conjugation or a complex with one or more small molecule drugs, protein therapeutics, or other dsRNA molecules. The present invention is directed at the methods of production for, methods of use of, and therapeutic utilities for RNAi co-interference therapy utilizing the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2008:354216 USPATFULL		
TITLE:	METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA		
INVENTOR(S):	Berry, David Arthur, Brookline, MA, UNITED STATES Afeyan, Noubar Boghes, Lexington, MA, UNITED STATES Varma, Chris, Lexington, MA, UNITED STATES		
PATENT ASSIGNEE(S):	Flagship Ventures, Cambridge, MA, UNITED STATES (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080311040	A1	20081218
APPLICATION INFO.:	US 2008-43029	A1	20080305 (12)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2007-893165P	20070306 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Noel E. Day, Miller, Canfield, Paddock & Stone, Suite 5000, 277 South Rose Street, Kalamazoo, MI, 49007, US		
NUMBER OF CLAIMS:	146		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	7473		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 42 USPATFULL on STN
TI Laminin-5 gamma2-binding peptides, related compositions, and use thereof
AB Novel peptides that specifically bind the γ2 chain of laminin-5 and other γ2-associated proteins; related compositions (e.g., derivatives and variants of such peptides; nucleic acids comprising sequences encoding such peptides; pharmaceutical compositions comprising either of such molecules; etc.); methods of using the same for diagnostic, prophylactic, and therapeutic purposes; and additional new and useful related compositions and methods are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2007:75097 USPATFULL
TITLE:	Laminin-5 gamma2-binding peptides, related compositions, and use thereof
INVENTOR(S):	Tryggvason, Karl, Djursholm, SWEDEN Mathiasen, Ida Stenfeldt, Kgs. Lyngby, DENMARK Padkaer, Soren Berg, Vaerlose, DENMARK Tarabykina, Svetlana, Frederiksberg, DENMARK Salo, Sirpa, Oulu, FINLAND

Boutaud, Ariel, Cary, NC, UNITED STATES
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, DENMARK (U.S. corporation)
BioStratum Incorporated, Durham, NC, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070065447	A1	20070322
APPLICATION INFO.:	US 2006-413663	A1	20060428 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2004-DK744, filed on 28 Oct 2004, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2003-EP12012	20031029

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVO NORDISK, INC., PATENT DEPARTMENT, 100 COLLEGE ROAD WEST, PRINCETON, NJ, 08540, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 13284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 42 USPATFULL on STN
TI Constructs binding to phosphatidylserine and their use in disease treatment
AB Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2006:267618 USPATFULL
TITLE: Constructs binding to phosphatidylserine and their use in disease treatment
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Luster, Troy A., Dallas, TX, UNITED STATES
King, Steven W., Ladera Ranch, CA, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)
Peregrine Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060228299	A1	20061012
APPLICATION INFO.:	US 2006-339392	A1	20060124 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-646333P	20050124 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PEREGRINE PHARMACEUTICALS, INC., 5353 WEST ALABAMA, SUITE 306, HOUSTON, TX, 77056, US

NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 12525
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 42 USPATFULL on STN
TI Cancer treatment kits using antibodies to aminophospholipids
AB Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2006:167038 USPATFULL
TITLE: Cancer treatment kits using antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Dallas, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060141545	A1	20060629
APPLICATION INFO.:	US 2006-329293	A1	20060110 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-351862, filed on 12 Jul 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92672P	19980713 (60)
	US 1998-110608P	19981202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PEREGRINE PHARMACEUTICALS, INC., 5353 WEST ALABAMA, SUITE 306, HOUSTON, TX, 77056, US
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 7270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 42 USPATFULL on STN
TI Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of

specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:162122 USPATFULL
TITLE:	Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
INVENTOR(S):	Thorpe, Philip E., Dallas, TX, UNITED STATES Ran, Sophia, Dallas, TX, UNITED STATES Brekken, Rolf A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System, Austin, TX, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7067109	B1	20060627
APPLICATION INFO.:	US 1999-351149		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Padmanabhan, Sreeni
ASSISTANT EXAMINER:	Sharareh, Shahnam
LEGAL REPRESENTATIVE:	Fussey, Shelley P. M.
NUMBER OF CLAIMS:	35
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT:	8637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 42 USPATFULL on STN

TI Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids

AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:98579 USPATFULL
TITLE:	Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
INVENTOR(S):	Thorpe, Philip E., Dallas, TX, UNITED STATES Ran, Sophia, Dallas, TX, UNITED STATES Brekken, Rolf A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060083745	A1	20060420

APPLICATION INFO.: US 2005-254137 A1 20051019 (11)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-351149, filed on 12 Jul 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PEREGRINE PHARMACEUTICALS, INC., 5353 WEST ALABAMA, SUITE 306, HOUSTON, TX, 77056, US
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 8215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 42 USPATFULL on STN
TI Modified plasminogen inhibitor type-1 and methods based thereon
AB The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfliydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyerfibrinolysis, hemophilia, and vessel leakage syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:182912 USPATFULL
TITLE: Modified plasminogen inhibitor type-1 and methods based thereon
INVENTOR(S): Swiercz, Rafal, Bastrop, TX, UNITED STATES
Selman, Steven H., Toledo, OH, UNITED STATES
Jankun, Jerzy, Sylvania, OH, UNITED STATES
Skrzypczak-Jankun, Ewa, Sylvania, OH, UNITED STATES
Chorostowska-Wynimko, Joanna, Warsaw, POLAND

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050158295	A1	20050721	
APPLICATION INFO.:	US 2003-506406	A1	20030304	(10)
	WO 2003-US6679		20030304	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361670P	20020304 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 3399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 42 USPATFULL on STN
TI Cancer treatment methods using selected antibodies to aminophospholipids
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:157851 USPATFULL
TITLE: Cancer treatment methods using selected antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050136059	A1	20050623
APPLICATION INFO.:	US 2003-642071	A1	20030815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 42 USPATFULL on STN
TI Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:150785 USPATFULL
TITLE: Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050129696	A1	20050616
APPLICATION INFO.:	US 2003-642065	A1	20030815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 42 USPATFULL on STN
TI Antibody conjugate methods for selectively inhibiting VEGF
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:143802 USPATFULL
TITLE: Antibody conjugate methods for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Brekken, Rolf A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050123537	A1	20050609
APPLICATION INFO.:	US 2003-738404	A1	20031217 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-561005, filed on 28 Apr 2000, GRANTED, Pat. No. US 6703020

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Shelley P.M. Fussey, Ph.D., WILLIAMS, MORGAN & AMERSON, P.C., 10333 Richmond, Suite 1100, Houston, TX, 77042, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1-2
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 10237

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 42 USPATFULL on STN

TI Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases

AB This invention pertains to methods for imaging the activity of extracellular proteases in cells using the anthrax binary toxin-system to target cells expressing extracellular proteases with mutant anthrax toxin protective antigens (μPrAg) that bind to receptors on the cells and are cleaved by a specific extracellular protease expressed by the cells, and ligands that specifically bind to the cleaved μPrAg and are linked to a moiety that is detectable by an imaging procedure. The μPrAg proteins used in the methods comprise a protease cleavage site that is cleaved by a specific extracellular protease and is in place of the furin cleavage site of the native PrAg. The methods are useful for diagnosing and treating diseases and undesirable physiological conditions correlated with the activity of extracellular proteases, and for optimizing the therapeutic efficacy of drugs used to treat such diseases and conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:143741 USPATFULL
TITLE:	Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
INVENTOR(S):	Bugge, Thomas H., Bethesda, MD, UNITED STATES Leppla, Stephen H., Bethesda, MD, UNITED STATES Liu, Shi-Hui, Rockville, MD, UNITED STATES Mitola, David, Baltimore, MD, UNITED STATES
PATENT ASSIGNEE(S):	The Government of the United States as represented by the Secretary of the Department of Health and, Rockville, MD, UNITED STATES, 20852-3804 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050123476	A1	20050609	
APPLICATION INFO.:	US 2003-488806	A1	20020905	(10)
	WO 2002-US28397		20020905	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-317550P	20010905 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 94111, US
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
LINE COUNT:	4268

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 42 USPATFULL on STN

TI Antibody kits for selectively inhibiting VEGF

AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and

prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:107236 USPATFULL		
TITLE:	Antibody kits for selectively inhibiting VEGF		
INVENTOR(S):	Thorpe, Philip E., Dallas, TX, UNITED STATES Brekken, Rolf A., Seattle, WA, UNITED STATES		
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System, Austin, TX, UNITED STATES (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6887468	B1	20050503
APPLICATION INFO.:	US 2000-562245		20000428 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1999-131432P		19990428 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Nickol, G.		
ASSISTANT EXAMINER:	Yaen, C.		
LEGAL REPRESENTATIVE:	Williams, Morgan and Amerson		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	10510		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 42 USPATFULL on STN

TI Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids

AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:104590 USPATFULL		
TITLE:	Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids		
INVENTOR(S):	Thorpe, Philip E., Dallas, TX, UNITED STATES Ran, Sophia, Dallas, TX, UNITED STATES Brekken, Rolf A., Seattle, WA, UNITED STATES		
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050089523	A1	20050428
APPLICATION INFO.:	US 2004-988245	A1	20041112 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-351598, filed on 12 Jul 1999, GRANTED, Pat. No. US 6818213		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1-63
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 8230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 42 USPATFULL on STN
TI Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:69437 USPATFULL
TITLE: Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Soares, M. Melina, Richardson, TX, UNITED STATES
He, Jin, Dallas, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050059578	A1	20050317
	US 7511124	B2	20090331
APPLICATION INFO.:	US 2003-642121	A1	20030815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e swiercz, r/au
E1 7 SWIERCZ WALDEMAR/AU
E2 5 SWIERCZ WILLIAM D/AU
E3 0 --> SWIERCZ, R/AU

```
E4            6     SWIERCZAK AGNIESZKA/AU
E5            2     SWIERCZAK J/AU
E6            1     SWIERCZAK JANUSZ/AU
E7            1     SWIERCZAK K/AU
E8            3     SWIERCZAK KAZIMIERZ/AU
E9            1     SWIERCZAK ROMAN/AU
E10           3     SWIERCZAK SABINA/AU
E11          32     SWIERCZEK/AU
E12           2     SWIERCZEK A/AU

=> e selman, s/au
E1            1     SELMAN WARREN S/AU
E2            1     SELMAN WILLIAM A/AU
E3            0 --> SELMAN, S/AU
E4            2     SELMANAGIC ALMIRA/AU
E5            1     SELMANAGIC I/AU
E6            1     SELMANE A/AU
E7            1     SELMANE D/AU
E8            1     SELMANE DARINE/AU
E9            3     SELMANE M/AU
E10           1     SELMANE MOHAMED/AU
E11           2     SELMANE T/AU
E12          13     SELMANE TASSADITE/AU

=> e jankun, j/au
E1            8     JANKUN THOMAS/AU
E2            1     JANKUN THOMAS M/AU
E3            0 --> JANKUN, J/AU
E4            8     JANKUNAITE D/AU
E5            1     JANKUNAITE DALIA/AU
E6            2     JANKUNAITE E/AU
E7            1     JANKUNAS/AU
E8            6     JANKUNAS A/AU
E9            1     JANKUNAS A A/AU
E10           2     JANKUNAS ANTANAS/AU
E11           2     JANKUNAS HOPE/AU
E12           2     JANKUNAS HOPE J/AU

=> e skrzypczak, j/au
E1            4     SKRZYPCZAK WLODZIMIERZ/AU
E2            4     SKRZYPCZAK WOJCIECH/AU
E3            0 --> SKRZYPCZAK, J/AU
E4            1     SKRZYPCZAKA/AU
E5            1     SKRZYPCZAKOVA LUTOSLAWA/AU
E6            1     SKRZYPCZAKOWA ANDELLNAIN WOJTASZEK L M/AU
E7            9     SKRZYPCZAKOWA L/AU
E8           27     SKRZYPCZAKOWA LUTOSLAWA/AU
E9            1     SKRZYPCZEK E/AU
E10           1     SKRZYPCZKY LECH/AU
E11           1     SKRZYPCZNSKI/AU
E12          15     SKRZYPCZNSKI Z/AU

=> d his

     (FILE 'HOME' ENTERED AT 12:54:06 ON 20 APR 2009)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, HCAPLUS, BIOTECHDS'
     ENTERED AT 12:55:08 ON 20 APR 2009
L1          406 S (PAI-1 AND DISULFIDE BOND)
L2           69 S L1 AND (SULFHYDRYL GROUP)
L3           66 S L2 AND (CYSTEINE)
```

```
L4          61 S L2 AND (POSITION 31 OR 97)
L5          42 S L4 AND (POSITION 192 OR 197)
               E SWIERCZ, R/AU
               E SELMAN, S/AU
               E JANKUN, J/AU
               E SKRZYPCZAK, J/AU

=>
```